NCT00217737 2026-03-18
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
1,548 trialsNCT00980460 2026-03-18
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
NCT02997228 2026-03-18
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03775265 2026-03-18
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04929028 2026-03-18
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT06654037 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06696768 2026-03-18
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06770582 2026-03-18
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04083599 2026-03-16
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT05253651 2026-03-16
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT06469944 2026-03-16
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07472868 2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3 Not yet recruiting
NCT06131840 2026-03-13
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06704724 2026-03-13
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Active not recruiting
NCT07024615 2026-03-13
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT06011772 2026-03-11
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT05239741 2026-03-10
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06269978 2026-03-10
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06780111 2026-03-10
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07069712 2026-03-10
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
NCT05229497 2026-03-09
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Akeso
Phase 1/2 Active not recruiting
NCT05491512 2026-03-09
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06764875 2026-03-09
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
Phase 3 Recruiting
NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
NCT04380545 2026-03-06
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04847063 2026-03-06
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07070466 2026-03-06
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Massachusetts General Hospital
Phase 2 Recruiting
NCT00707473 2026-03-05
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02890355 2026-03-05
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04230187 2026-03-05
TRIBE-C
Sun Yat-sen University
Phase 3 Recruiting
NCT04522336 2026-03-05
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04683315 2026-03-05
PANCREAS
Medical College of Wisconsin
Phase 2 Recruiting
NCT05721755 2026-03-05
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05568095 2026-03-04
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT05677490 2026-03-04
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05846867 2026-03-04
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase 1/2 Active not recruiting
NCT06951503 2026-03-04
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Akeso
Phase 3 Recruiting
NCT00588770 2026-03-03
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04094688 2026-03-03
SOLARIS
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04215731 2026-03-03
FOBEAR
Sun Yat-sen University
Phase 3 Recruiting
NCT06057038 2026-03-03
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Phase 1 Active not recruiting